ArticleInternational journal of colorectal disease2025
ERO1α regulates colon cancer progression and 5-FU resistance through the miR-451a/ARF1 axis.
Article in International journal of colorectal disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mechanisms and advances of drug resistance in colorectal cancer: A systematic overview of multi-layered regulatory networks.Translational oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundColon cancer (CC) is one of the three most common cancers worldwide. In the treatment of CC, 5-fluorouracil (5-FU) is one of the main components of chemotherapeutic combinations, but severe chemical resistance still occurs. In addition, endoplasmic reticulum (ER) oxidoreductase-1α (ERO1α) has been shown to be highly expressed in CC, but its specific molecular mechanisms remain unclear.
methodsVia western blot, real-time quantitative polymerase chain reaction (RT‒qPCR), colony formation, Transwell, CCK-8, immunofluorescence, and immunohistochemistry experiments,we evaluated the expression of related genes and the progression of CC.
resultsIn this study, we found that ERO1α was highly expressed in CC and that miR-451a expression was low. Knocking down ERO1α can restrain the proliferation and invasion of CC cells; facilitate the expression of the ER stress-related proteins inositol-requiring enzyme (IRE), phosphorylated IRE (Pho-IRE), glucose-regulated protein 78 (GRP78), and activating transcription factor 4 (ATF4) and the proapoptotic proteins Bcl-2-associated X protein (Bax) and cleaved-caspase-3 in CC cells; and alleviate the progression of CC. The addition of the miR-451a inhibitor weakened the effect of sh-ERO1α. In terms of mechanism, we predicted that miR-451a targets ADP-ribosylation factor 1 (ARF1) through the StarBase website and confirmed the interaction between the two through a dual-luciferase gene reporter assay. Next, we verified that knocking down ERO1α promoted miR-451a and inhibited ARF1 expression, thus promoting ER stress and ultimately inhibiting the progression of CC. In addition, knocking down ERO1α promoted ER stress and weakened CC cell resistance to 5-FU.
conclusionOur studies revealed that ERO1α could mediate ER stress to regulate the progression of CC and 5-FU resistance through the miR-451a/ARF1 axis, which may provide new treatment directions and molecular targets for CC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.